Aging of the Peritoneal Dialysis Membrane

Area of Science:

• Nephrology
• Cell Biology
• Biochemistry

Background:

• Peritoneal dialysis (PD) is a life-sustaining treatment for kidney failure.
• Long-term PD using glucose-based solutions leads to structural and functional decline of the peritoneal membrane.
• This decline can result in ultrafiltration failure, a major complication of PD.

Purpose of the Study:

• To review the alterations in peritoneal membrane function and morphology during long-term PD.
• To discuss the pseudohypoxia hypothesis as a mechanism for glucose-induced peritoneal damage.
• To explore current and emerging strategies for preventing and treating these PD-related complications.

Main Methods:

• Review of existing literature on peritoneal dialysis, membrane alterations, and the pseudohypoxia hypothesis.
• Analysis of the role of hypoxia-inducing factor-1 (HIF-1) and its downstream targets (e.g., GLUT-1, TGF-β, VEGF).
• Evaluation of therapeutic interventions and novel approaches in PD fluid composition and adjunct therapies.

Main Results:

• Continuous exposure to glucose in PD solutions induces pseudohypoxia in the peritoneum.
• Pseudohypoxia upregulates HIF-1, leading to increased expression of GLUT-1, growth factors (TGF-β, VEGF, CTGF), and PAI-1.
• This upregulation, particularly GLUT-1 in fibroblasts, creates a cycle exacerbating ultrafiltration failure.

Conclusions:

• Pseudohypoxia is a key mechanism explaining peritoneal membrane alterations in long-term PD.
• Low-glucose degradation product/neutral pH, bicarbonate-buffered solutions with low concentrations of osmotic agents are currently optimal.
• Adjunct therapies like RAAS inhibitors, tamoxifen, alanyl glutamine, and potentially nicotinamide mononucleotide show promise for improving PD outcomes.